Research
Hormonal
Rapid weight gain in infancy, often driven by high protein intake in infant formula, is associated with an increased risk of later obesity and adverse metabolic outcomes.
If using infant formula, consider one with lower protein content, as it is associated with a lower risk of obesity at age 14-16 years. Breastfeeding is also protective. Monitor your infant's growth curve to ensure steady, not rapid, weight gain.
GoodSupportsHIGH confidence
accelerated postnatal weight gain can result from high intake of growth-enhancing nutrients such as protein in the infant diet... higher protein intakes increase plasma and tissue levels of insulin-releasing amino acids and of insulin and insulin-like growth factor 1, and thereby increase weight gain and adipogenic activity
Why this rating
Supported by meta-analyses and randomized controlled trials comparing protein levels in formula.
Source
Early nutrition programming of long-term health
Berthold Koletzko et al. · Proceedings of The Nutrition Society · 2012
DOI 10.1017/s0029665112000596
narrative_reviewCited 226×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Intrauterine exposure to excess fuels, particularly glucose, causes permanent fetal changes that lead to accelerated postnatal weight gain and increased risk of obesity in postnatal life.Good
- A developmental mismatch between a sub-optimal pre-natal/infant environment (e.g., low birth weight, poor growth) and an obesogenic childhood environment predisposes individuals to obesity and related co-morbidities.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →